Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

A Therapeutic Vaccine for ALS Directed Against Misfolding Specific Epitopes of Cu/Zn Superoxide Dismutase

EF 2009-10

Résumé
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease that results in the degeneration of motor neurons and afflicts ~30,000 individuals in North America, with 5,000 new cases per year. About 20% of familial ALS is associated with mutations in the gene encoding Cu/Zn Superoxide Dismutase (SOD1). When properly folded and functional, SOD1 is an intracellular antioxidant that forms the first line of defence against free radicals, which cause oxidative stress. There is growing evidence supporting that ALS pathogenesis is associated with SOD1 misfolding, oxidation and aggregation. The Cashman Lab has identified a series of Disease Specific Epitopes (DSEs) that are buried in natively folded SOD1, but are predicted to be exposed on the molecular surface of misfolded SOD1. My project will confirm and extend the therapeutic effectiveness and safety of DSE1a and DSE2 peptides, two of the best described DSEs, in active vaccination of two strains of mice that express different mutants of SOD1 that vary in their onset and progression of disease. The target of this vaccine is a region of SOD1 that is not exposed in natively folded SOD1 and thus adverse events from autoimmune responses are not expected. This serves as an additional safety mechanism to prevent the vaccine from attacking the properly structured, functional, SOD1 protein. Clearly, a therapeutic vaccine would have enormous impact on ALS patients and their families. Perhaps the largest impact would be the development of an effective prophylactic vaccine for ALS, to be provided to subjects with family history of ALS, with or without mutations, and others that are at high risk due to environmental factors.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
201574
Name
Pokrishevsky Edward
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
A Therapeutic Vaccine for ALS Directed Against Misfolding Specific Epitopes of Cu/Zn Superoxide Dismutase
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Active Vaccination; Amyotrophic Lateral Sclerosis (Als); Cu/Zn Superoxide Dismutase (Sod1); Flow Cytometry; Immunofluorescence; Microscopy; Neurodegeneration; Protein Misfolding; Therapeutic Vaccination; Western Blotting
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease that results in the degeneration of motor neurons and afflicts ~30,000 individuals in North America, with 5,000 new cases per year. About 20% of familial ALS is associated with mutations in the gene encoding Cu/Zn Superoxide Dismutase (SOD1). When properly folded and functional, SOD1 is an intracellular antioxidant that forms the first line of defence against free radicals, which cause oxidative stress. There is growing evidence supporting that ALS pathogenesis is associated with SOD1 misfolding, oxidation and aggregation. The Cashman Lab has identified a series of Disease Specific Epitopes (DSEs) that are buried in natively folded SOD1, but are predicted to be exposed on the molecular surface of misfolded SOD1. My project will confirm and extend the therapeutic effectiveness and safety of DSE1a and DSE2 peptides, two of the best described DSEs, in active vaccination of two strains of mice that express different mutants of SOD1 that vary in their onset and progression of disease. The target of this vaccine is a region of SOD1 that is not exposed in natively folded SOD1 and thus adverse events from autoimmune responses are not expected. This serves as an additional safety mechanism to prevent the vaccine from attacking the properly structured, functional, SOD1 protein. Clearly, a therapeutic vaccine would have enormous impact on ALS patients and their families. Perhaps the largest impact would be the development of an effective prophylactic vaccine for ALS, to be provided to subjects with family history of ALS, with or without mutations, and others that are at high risk due to environmental factors.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pokrishevsky, Edward
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~